The Role of Adjuvant Therapy After Liver Resection for Colorectal Cancer Metastase

2001 ◽  
Vol 1 (3) ◽  
pp. 154-166 ◽  
Author(s):  
Leyo Ruo ◽  
Ronald P. DeMatteo ◽  
Leslie H. Blumgart
Keyword(s):  
Colorectal Cancer ◽  
Liver Resection ◽  
Adjuvant Therapy

LIver Resection and role of Extended Histology (LiREcH study) in patients with multifocal colorectal cancer liver metastases

HPB ◽  
2021 ◽  
Author(s):  
Hassaan Bari ◽  
Umasankar M. Thiyagarajan ◽  
Rachel Brown ◽  
Keith J. Roberts ◽  
Nikolaos Chatzizacharias ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Resection ◽  
Liver Metastases ◽  
Colorectal Cancer Liver Metastases

The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: A systematic review

Surgery ◽  
2012 ◽  
Vol 151 (6) ◽  
pp. 860-870 ◽  
Author(s):  
Douglas Quan ◽  
Steven Gallinger ◽  
Cindy Nhan ◽  
Rebecca A. Auer ◽  
James J. Biagi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Liver Resection ◽  
Multimodality Treatment ◽  
Cancer Metastases ◽  
Colorectal Cancer Metastases

scholarly journals The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer

1996 ◽  
Vol 7 (1) ◽  
pp. 41-46 ◽  
Author(s):  
J.R. Zalcberg ◽  
J. Siderov ◽  
J. Simes
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Therapy

scholarly journals Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3892
Author(s):  
Kaisa Lehtomäki ◽  
Harri Mustonen ◽  
Pirkko-Liisa Kellokumpu-Lehtinen ◽  
Heikki Joensuu ◽  
Kethe Hermunen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Therapy ◽  
Lead Time ◽  
Disease Free Survival ◽  
Phase Iii ◽  
Lead Times ◽  
Curative Intent ◽  
Serum Cea ◽  
Resected Stage

In colorectal cancer (CRC), 20–50% of patients relapse after curative-intent surgery with or without adjuvant therapy. We investigated the lead times and prognostic value of post-adjuvant (8 months from randomisation to adjuvant treatment) serum CEA, CA19-9, IL-6, CRP, and YKL-40. We included 147 radically resected stage II–IV CRC treated with 24 weeks of adjuvant 5-fluorouracil-based chemotherapy in the phase III LIPSYT-study (ISRCTN98405441). All 147 were included in lead time analysis, but 12 relapsing during adjuvant therapy were excluded from post-adjuvant analysis. Elevated post-adjuvant CEA, IL-6, and CRP were associated with impaired disease-free survival (DFS) with hazard ratio (HR) 5.21 (95% confidence interval 2.32–11.69); 3.72 (1.99–6.95); 2.58 (1.18–5.61), respectively, and elevated IL-6 and CRP with impaired overall survival (OS) HR 3.06 (1.64–5.73); 3.41 (1.55–7.49), respectively. Elevated post-adjuvant IL-6 in CEA-normal patients identified a subgroup with impaired DFS. HR 3.12 (1.38–7.04) and OS, HR 3.20 (1.39–7.37). The lead times between the elevated biomarker and radiological relapse were 7.8 months for CEA and 10.0–53.1 months for CA19-9, IL-6, CRP, and YKL-40, and the lead time for the five combined was 27.3 months. Elevated post-adjuvant CEA, IL-6, and CRP were associated with impaired DFS. The lead time was shortest for CEA.

Role of Adjuvant Therapy After Resection of Colorectal Cancer Liver Metastases

2010 ◽  
Vol 28 (13) ◽  
pp. 2300-2309 ◽  
Author(s):  
Derek G. Power ◽  
Nancy E. Kemeny
Keyword(s):  
Colorectal Cancer ◽  
Liver Resection ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Liver Metastases ◽  
Metastatic Colorectal Cancer ◽  
Adjuvant Treatment ◽  
Systemic Chemotherapy ◽  
Perioperative Therapy

Liver resection is the goal of treatment strategies for liver-confined metastatic colorectal cancer. However, after resection the majority of patients will experience recurrence. Chemotherapy seems to improve outcomes compared with surgery alone. We reviewed the data of the role of adjuvant chemotherapy after resection of liver- confined metastatic colorectal cancer. Optimal regimens and sequencing of chemotherapies when liver resection is an option are unclear. Some suggest that resectable liver metastases, in the absence of high-risk features, should begin with surgery and consideration given to adjuvant chemotherapy after surgery. If high-risk features are present, most physicians prefer a short course of systemic preoperative chemotherapy. Perioperative therapy and regional therapy with hepatic arterial infusion (HAI) both increase disease-free survival (DFS) when compared with surgery alone. In unresectable disease, consideration should be given to systemic chemotherapy with or without a biologic agent or HAI with systemic therapy. If the disease becomes resectable, adjuvant treatment should follow surgery. Adjuvant chemotherapy is usually FOLFOX, but HAI combined with systemic chemotherapy is also an option. The role of adjuvant treatment post-liver resection should not be viewed in isolation but rather in the context of prior treatment, surgical preference, and individual patient characteristics. Perioperative therapy and regional therapy have both shown an increase in DFS. Conducting randomized trials examining the role of adjuvant chemotherapy has been difficult because of rapidly changing chemotherapies.

Sign in / Sign up

Export Citation Format

Share Document